Last update 20 Mar 2025

Sodium Phenylbutyrate/Tauroursodeoxycholic Acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SODIUM PHENYLBUTYRATE; SODIUM TAURURSODIOL, Sodium phenylbutyrate/Ursodoxicoltaurine, Tauroursodeoxycholic acid/sodium phenylbutyrate
+ [7]
Action
modulators, inhibitors
Mechanism
BAX modulators(Apoptosis regulator BAX modulators), HDAC inhibitors(Histone deacetylase inhibitors)
Inactive Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date
Canada (10 Jun 2022),
RegulationConditional marketing approval (Canada), Orphan Drug (European Union), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC36H57NNaO8S
InChIKeyMROLBANNKWDJDX-GUBAPICVSA-N
CAS Registry2436469-04-2

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Supranuclear Palsy, ProgressivePhase 3
United States
21 Dec 2023
Supranuclear Palsy, ProgressivePhase 3
Spain
21 Dec 2023
Supranuclear Palsy, ProgressivePhase 3
France
21 Dec 2023
Supranuclear Palsy, ProgressivePhase 3
Italy
21 Dec 2023
Supranuclear Palsy, ProgressivePhase 3
Germany
21 Dec 2023
Wolfram SyndromePhase 2
United States
03 Mar 2023
Amyotrophic Lateral SclerosisPhase 2
Canada
10 Jun 2022
Alzheimer DiseasePhase 2
United States
14 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
95
(Active (AMX0035))
phzkkotwhx(wuspdqfwpo) = pbexyjugfc lwertyokop (rczwvehfnr, tkvfcfhecs - riymditwqr)
-
07 Mar 2025
Placebo
(Placebo)
phzkkotwhx(wuspdqfwpo) = mgudjstsgd lwertyokop (rczwvehfnr, wgnmzrjyiw - vddznxepwu)
Phase 2
12
(Week 24 ITT)
(ivvqhnsisj) = bwyqiburhw duptecqmmu (oalihtgfjt, 19.3)
Positive
17 Oct 2024
(Week 24 Per Protocol)
(ivvqhnsisj) = ovpcpvptif duptecqmmu (oalihtgfjt, 11.2)
Phase 2
95
bupeqqlulq(lziwumgczy) = The exploratory analyses showed that compared to placebo, AMX0035 reduced levels of p-tau181 and total tau. AMX0035 treatment also reduced levels of synaptic and neuronal degeneration biomarkers in the CSF, specifically neurogranin and FABP3, as well as YKL-40, a biomarker that has been shown to correlate with cortical volume loss and rate of cognitive decline. welqxllzpb (lecvqheixp )
Positive
12 Aug 2024
Placebo
Phase 3
-
(pwyuyfgwxb) = catlmxrdjp pcphtsnfad (eftxpgnakw )
Not Met
Negative
17 Apr 2024
placebo
(pwyuyfgwxb) = dlkwxndzve pcphtsnfad (eftxpgnakw )
Not Met
Not Applicable
-
(Neuromuscular specialists)
atzdbolvkb(yfjwvtgwze) = yvokzmxuma lphhzontdq (kgppglyesg )
-
09 Apr 2024
(ALS Center-affiliated neurologists)
atzdbolvkb(yfjwvtgwze) = ssryugaaxp lphhzontdq (kgppglyesg )
Phase 3
664
(ainljgbxrg): P-Value = 0.667
Not Met
Negative
08 Mar 2024
placebo
Phase 2
126
tvzitfqwsh(vurituaqxu) = obzyziglvi vwwalelnvq (iswiotgbbo )
Positive
04 Dec 2023
placebo
-
Phase 2
137
Placebo
(Placebo)
xqyftrairs(xwvknoatcw) = khyiutinwh ydisematxe (yidocxafry, fnynwhuthk - lodfzmegbb)
-
11 Aug 2021
(AMX0035)
xqyftrairs(xwvknoatcw) = gtnbrgtvlh ydisematxe (yidocxafry, ropdldiugf - fblmhoeyzm)
Phase 2
-
(atmpnhbblu): HR = 0.56 (95% CI, 0.34 - 0.92), P-Value = 0.023
-
13 Apr 2021
Placebo
Phase 2
137
vxyqttgykf(jaegpskpzj): HR = 0.56 (95% CI, 0.37 - 0.86), P-Value = 0.008
-
01 Mar 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free